UBS analyst Jay Sole raised the firm’s price target on Bath & Body Works to $21 from $17 and keeps a Neutral rating on the shares. CY26 EPS upside for Softline stocks is expected to be driven by a stronger-than-expected U.S. consumer and an underappreciated “Health & Wellness 2.0” trend, with estimates at least 4% above consensus for 16 names, the analyst tells investors in a research note. Earnings momentum is projected to extend into CY27, with EPS forecasts averaging about 5% above consensus, the firm adds.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBWI:
- Bath & Body Works price target raised to $20 from $18 at Barclays
- This Year’s Santa Rally Isn’t About Gains, It’s About Holding the Line
- Bath & Body Works price target raised to $20 from $19 at Baird
- Unusually active option classes on open December 15th
- Amazon initiated, GE Vernova upgraded: Wall Street’s top analyst calls